Epidemiological and Pharmacoeconomic Aspects of Alzheimer

1
Epidemiological and Pharmacoeconomic Aspects of
Alzheimers Disease and Dementia
2
Age Distribution of the World Population
Age
United Nations Economic and Social Council 2000
3
Average Annual Growth Rates of the World
Population
Average Annual Growth (2000-2050 Medium variant)
4 3 2 1 0 -1
3.39
2.29
Percentage ()
0.72
-0.04
014
1559
60
80
Age
World Population Prospects, The 2002 Revision
4
Prevalence of Dementia
World (estimated)
25 20 15 10 5 0
23.6
Prevalence Rate ()
11.1
5.6
2.8
1.4
6569
7074
7579
8084
85
Age
Jorm et al., Acta Psychiatrica Scandinavica 1987
5
Types of Dementia
Europe
North America
11.0
15.5
10.0
61.4
27.6
74.5
Asia
15.4
46.5
38.1
? Alzheimers disease ? Vascular dementia ? Other
Fratiglioni et al., Drugs Aging 1999
6
Caregiver Costs Increase with Increasing Severity
of Dementia (Germany)
16,000 12,000 8,000 4,000
? Community Setting ? Institutional Setting
Annual Costs ()
MMSE 2621
MMSE 2015
MMSE 1410
MMSE lt10
Hallauer, 2002
7
Diagnosis and Treatment Statistics of Alzheimers
Disease

• On average AD patients live 8 to 10 years after
  diagnosis
• AD can last for up to 20 years

Cognos Report, 2002
8
Potential to Reduce Caregiver Time Increases with
Severity of the Disease
1Dement Geriatr Cogn Disord 2003 Erratum
2003 2Chemical Business News Base 2001 3 Wimo et
al., Pharmacoeconomics 2003
Figure adapted according to references
9
Specific Aspects of Moderate to Severe
Alzheimers Diseases

• Caregiver burden and cost of illness is high in
  patients with moderate to severe AD
• A treatment which is efficacious in these stages
  is expected to reduce caregiver and societal cost
• Memantine treatment has been shown to reduce
  caregiver and societal costs (Wimo et al., 2003)